Ontario Sun - ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Innovations

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $100,000 milestone licensing payment from ForSeeCon Eye Corporation, marking a significant step forward in their partnership to develop and commercialize drugs for ophthalmic indications. This payment contributes to ABVC’s cumulative licensing revenue, now totaling $946,000, and underscores the potential for the partnership’s value to reach up to $1.0 billion, considering product valuations, equity, royalties, and performance-based payouts.

The collaboration between ABVC and ForSeeCon focuses on Vitargus®, a next-generation vitreous substitute, targeting the expansive global eye care market, projected to reach $110.3 billion by 2030. Dr. Uttam Patil, ABVC’s CEO, emphasized the importance of this milestone as a reflection of the company’s commitment to addressing unmet needs in ophthalmology through innovation and advanced biologic solutions. The payment also provides non-dilutive capital to support further development phases, with growing international interest in Vitargus® from partners in Europe and Japan.

Mr. Jerry Chang, CEO of ForSeeCon Eye Corporation, expressed pride in the collaboration’s progress and the global enthusiasm for Vitargus®, which is seen as a potential game-changer in retinal surgery outcomes. The companies plan to initiate pivotal clinical trials in key international markets in 2025, further solidifying their position in the ophthalmology sector.

ABVC’s strategic roadmap is bolstered by this latest payment, following multiple late-stage CNS licensing deals and expansion into oncology. With licensing income expected to continue into the second half of 2025, ABVC remains focused on capital-efficient innovation and unlocking value through global co-development partnerships. The company’s product pipeline, including Vitargus®, is viewed as having excellent market potential, supported by the projected growth of the global eye care market at a compound annual growth rate of 6.9% from 2024 to 2030.